← Back to Clinical Trials
Recruiting NCT06663111

NCT06663111 Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06663111
Status Recruiting
Phase —
Sponsor Haukeland University Hospital
Condition Relapsing Remitting Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2021-03-15
Primary Completion 2025-12

Trial Parameters

Condition Relapsing Remitting Multiple Sclerosis
Sponsor Haukeland University Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2021-03-15
Completion 2025-12
Interventions
Blood samples for PKBlood samples for PK

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Eligibility Criteria

Inclusion Criteria: * Included in OVERLORD-MS (NCT04578639) * Willing to attend laboratory for blood sample collection at scheduled time points Exclusion criteria: \* Not willing to attend laboratory for blood sample collection at scheduled time points

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

VIEW ON CLINICALTRIALS.GOV ↗ MORE RELAPSING REMITTING MULTIPLE SCLEROSIS TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology